Headlines
Headlines

UCB to acquire Zogenix for nearly $2B

Brussels, BE, and Emeryville, CA, January 19, 2022 (PRNewswire) — Regulated information – Inside information – UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced today that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases. Under the terms of the agreement, UCB will commence a tender offer to purchase all outstanding shares of Zogenix for a purchase price per share of US$ 26.00 in cash at closing, plus a contingent value right (CVR) for a potential cash payment of US$ 2.00 upon EU approval by December 31, 2023, of FINTEPLA® as an orphan medicine for treatment of Lennox-Gastaut syndrome (LGS). The upfront consideration represents a 72% premium to Zogenix shares based on the 30-day volume weighted average closing stock price of Zogenix prior to signing. The total transaction is valued at up to approximately US$ 1.9 billion / € 1.7 billion. More

Read More »
Headlines
Headlines

Altos Labs Launches Biotechnology Company with $3B and Hal Barron (President of R&D and CSO at GSK) Leading a Dream Team

San Francisco, CA, January 19, 2022 (PRNewswire)  — Altos Labs™ (Altos™) launched today as a new biotechnology company dedicated to unraveling the deep biology of cellular rejuvenation programming. Altos’ mission is to restore cell health and resilience to reverse disease, injury, and the disabilities that can occur throughout life. The company launches with a community of leading scientists, clinicians, and leaders from both academia and industry working together towards this common mission. More

Read More »
Headlines
Headlines

BiVACOR® Taps Prominent Medical Device Leader and Former Cardiac Surgeon Thomas Vassiliades as New CEO

Houston, TX, January 14, 2022 (EINPresswire.com) — BiVACOR®, a preclinical artificial heart device company, has named Thomas Vassiliades, MD, MBA, as Chief Executive Officer effective immediately. Founder and previous CEO, Daniel Timms, Ph.D., tapped Dr. Vassiliades to build upon the foundation of innovative technology established over recent years and accelerate the progression of product development leading to human clinical trials and commercialization of the company’s novel and proprietary total artificial heart. More

Read More »
Headlines
Headlines

Korro Bio Completes $116M Series B Financing to Expand the Frontier of Genetic Medicine Through Its Pipeline of RNA Editing Programs

Cambridge, MA, January 05, 2022 (Business Wire) — Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced the completion of a $116M Series B financing. This financing will enable Korro to advance its lead program in development for patients with Alpha-1 Antitrypsin Deficiency (AATD), an inherited genetic disorder leading to liver and lung disease while expanding its pipeline to address prevalent diseases across multiple therapeutic areas. More

Read More »
Headlines
Headlines

Escient Pharmaceuticals Appoints Joshua Grass, MBA as CEO

San Diego, CA, January 5, 2022 (Business Wire) — Escient Pharmaceuticals, a clinical-stage company focused on discovering and developing novel, first-in-class therapies to address serious, unserved medical needs, today announced the appointment of Joshua Grass, MBA as Chief Executive Officer effective immediately. Mr. Grass will join the company’s Board of Directors. He succeeds Alain Baron, M.D., who recently retired and will remain a strategic advisor to Escient through the first quarter of 2022. More

Read More »
Headlines
Headlines

Catalent Announces Plan for Alessandro Maselli to Become New CEO Effective July 1, 2022

Somerset, N.J. January 5, 2022 (Business Wire) — Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies, as well as consumer health products, today announced that its Board of Directors has appointed Alessandro Maselli, currently President and Chief Operating Officer, as the company’s next President and Chief Executive Officer, effective July 1, 2022. Maselli will also join the company’s Board of Directors upon assuming his new role. Current Chair and Chief Executive Officer John Chiminski will remain in his present role until July 1, 2022, when he will assume the position of Executive Chair of the Board. More

Read More »
Headlines
Headlines

Thermo Fisher Scientific Completes Acquisition of PeproTech, a Leader in Recombinant Proteins

Waltham, MA, January 5, 2022 (PRNewswire) — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and PeproTech, Inc., a leading developer and manufacturer of recombinant proteins, today announced that Thermo Fisher completed its acquisition of PeproTech on December 30, 2021 for a total cash purchase price of approximately $1.85 billion. More

Read More »
Headlines
Headlines

Versantis Appoints Mark Fitzpatrick, Seasoned Biotech Executive, as its New CEO

Zurich, December 20, 2021 (BUSINESS WIRE) — Versantis, a clinical-stage biotechnology company developing novel therapies for orphan liver and pediatric diseases, today announced the appointment of Mark J. Fitzpatrick as Chief Executive Officer (CEO) and member of the board of directors, effective January 1, 2022. He joins Versantis with more than 25 years of experience in the biopharma industry, primarily in senior executive roles, and will be based in the U.S. following the establishment of Versantis, Inc. He succeeds co-founder Dr. Vincent Forster, who will assume the role of Chief Scientific Officer. More

Read More »
Headlines
Headlines

Verily expands Stephen Gillett’s role to President and Chief Operating Officer

South San Francisco, CA, December 20, 2021 (Verily) — Verily today announced the expansion of Stephen Gillett’s responsibilities, adding the title of President to his current role as Chief Operating Officer (COO). Gillett has held leadership and advisory roles at Google and across the Alphabet family for the past six years and joined Verily 18 months ago to drive operational, technical, cultural and strategic initiatives across the company. More

Read More »
Headlines
Headlines

Overjet Raises $42.5 Million Series B Following Explosive Customer Demand, Reaching $425 Million Valuation

Boston, MA, December 20, 2021 (PRNewswire) —  Amid accelerated demand for its dental artificial intelligence (AI) software, Overjet (www.overjet.ai) today announced it has raised $42.5 million in Series B financing led by General Catalyst and Insight Partners with participation from existing investors Crosslink Capital and the MIT-affiliated E14 Fund in an oversubscribed round. Following the $27 million Series A round announced, just four months ago, in August 2021, Overjet has raised nearly $80 million in total financing to date. More

Read More »